PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

被引：4

作者：

Brown, Fiona ^{[1
]}

Zhang, Yang ^{[2
]}

Hinterschied, Claire ^{[1
]}

Prouty, Alexander ^{[1
]}

Sloan, Shelby ^{[3
]}

Helmig-Mason, JoBeth ^{[3
]}

Chung, Ji Hyun ^{[1
]}

Vaddi, Kris ^{[2
]}

Chen-Kiang, Selina ^{[4
]}

Di Liberto, Maurizio ^{[4
]}

Alinari, Lapo ^{[1
]}

Scherle, Peggy ^{[2
]}

Lapalombella, Rosa ^{[3
]}

Paik, Jihye ^{[5
]}

Baiocchi, Robert A. ^{[6
]}

机构：

[1] Ohio State Univ, Div Hematol, Dept Internal Med, Coll Med, Columbus, OH USA

[2] Prelude Therapeut, Wilmington, DE USA

[3] Ohio State Univ, Div Hematol, Dept Internal Med, Columbus, OH USA

[4] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA

[5] Cornell Univ, Paik Lab, New York, NY 10021 USA

[6] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH 43210 USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-130797

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

302

引用

页数：4

共 50 条

[1] PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma
Brown-Burke, Fiona
Hwang, Inah
Sloan, Shelby
Hinterschied, Claire
Helmig-Mason, Jobeth
Long, Mackenzie
Chan, Wing Keung
Prouty, Alexander
Chung, Ji-Hyun
Zhang, Yang
Singh, Satishkumar
Youssef, Youssef
Bhagwat, Neha
Chen, Zhengming
Chen-Kiang, Selina
Di Liberto, Maurizio
Elemento, Olivier
Sehgal, Lalit
Alinari, Lapo
Vaddi, Kris
Scherle, Peggy
Lapalombella, Rosa
Paik, Jihye
Baiocchi, Robert A.
BLOOD ADVANCES, 2023, 7 (20) : 6211 - 6224
[2] PRMT5 Inhibition Promotes FOXO1 Tumor Suppressor Activity to Drive a Pro-Apoptotic Program That Creates Vulnerability to Combination Treatment with Venetoclax in Mantle Cell Lymphoma
Brown, Fiona
Hwang, Inah
Sloan, Shelby
Hinterschied, Claire
Helmig-Mason, Jo Beth
Long, Mackenzie
Youssef, Youssef
Chan, Wing Keung
Prouty, Alexander
Chung, Ji Hyun
Zhang, Yang
Vaddi, Kris
Chen-Kiang, Selina
Di Liberto, Maurizio
Elemento, Olivier
Sehgal, Lalit
Alinari, Lapo
Scherle, Peggy
Lapalombella, Rosa
Paik, Jihye
Baiocchi, Robert
BLOOD, 2021, 138
[3] PRMT5 inhibition alters mitochondrial dynamics in mantle cell lymphoma, creating vulnerability to BH3 mimetic compounds
Hinterschied, Claire
Brown, Fiona
Ravikrishnan, Janani
Helmig-Mason, JoBeth
Vaddi, Kris
Scherle, Peggy
Woyach, Jennifer
Chen-Kiang, Selina
Elemento, Oliver
Paik, Jihye
Baiocchi, Robert
CANCER RESEARCH, 2022, 82 (12)
[4] PRMT5 Inhibition Alters Mitochondrial Dynamics in Mantle Cell Lymphoma Creating Vulnerability to BH3 Mimetic Compounds
Hinterschied, Claire
Brown, Fiona
Ravikrishnan, Janani
Helmig-Mason, Jobeth
Harrison, Kaylee R.
Yasin, Aneeq
Sloan, Shelby
Long, Mackenzie
Bhagwat, Neha
Vaddi, Kris
Scherle, Peggy
Woyach, Jennifer A.
Chen-Kiang, Selina
Elemento, Olivier
Paik, Jihye
Baiocchi, Robert A.
BLOOD, 2022, 140 : 3118 - 3119
[5] Protein arginine methyltransferase 5 (PRMT5) inhibition as a therapeutic strategy in B-cell lymphoma
Barbash, Olena
Gerhart, Sarah
Soong, David
Thompson, Christine
de Oca, Rocio Montes
Zhang, Ping
McHugh, Charles
Kuplast, Kristy
Majer, Christina
Chesworth, Richard
Smith, Jesse
Copeland, Robert
Penebre, Elayne
Duncan, Kenneth
Johnson, Neil
Carpenter, Chris
Kruger, Ryan
CANCER RESEARCH, 2015, 75
[6] Acquired Resistance to PRMT5 Inhibition in Mantle Cell Lymphoma Is Associated with Compensatory Activation of Multiple Signaling Pathways
Long, Mackenzie
Koirala, Shirsha
Sloan, Shelby
Brown, Fiona
Tallada, Sheetal
Hinterschied, Claire
Corps, Kara
Helmig-Mason, Jobeth
Chung, Ji Hyun
Scherle, Peggy
Vaddi, Kris
Meydan, Cem
Foox, Jonathan
Butler, Daniel
Mason, Christopher E.
Alinari, Lapo
Blaser, Bradley W.
Baiocchi, Robert A.
BLOOD, 2022, 140 : 3103 - 3104
[7] Exploiting PRMT5, a metabolic and epigenetic regulator, as a novel therapeutic target in mantle cell lymphoma
Yao, Yixin
Li, Lingzhi
Zhang, Liang
Zhang, Shaojun
Guo, Hui
Zhang, Hui
Badillo, Maria
Chen, Zhihong
Hartig, Kimberly
Jain, Preetesh
Nomie, Krystle
Wang, Linghua
Wang, Michael
CANCER RESEARCH, 2020, 80 (16)
[8] Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations
Che, Yuxuan
Liu, Yang
Yao, Yixin
Hill, Holly A. A.
Li, Yijing
Cai, Qingsong
Yan, Fangfang
Jain, Preetesh
Wang, Wei
Rui, Lixin
Wang, Michael
BLOOD CANCER JOURNAL, 2023, 13 (01)
[9] Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations
Yuxuan Che
Yang Liu
Yixin Yao
Holly A. Hill
Yijing Li
Qingsong Cai
Fangfang Yan
Preetesh Jain
Wei Wang
Lixin Rui
Michael Wang
Blood Cancer Journal, 13
[10] Single Cell Transcriptomic Evolution and Resistance Mechanisms of BTK and BCL-2 Inhibition in Mantle Cell Lymphoma
Jiang, Vivian Changying
Zhang, Shaojun
Lian, Junwei
Wang, Yuanxin
Zhang, Rongjia
Liu, Yang
McIntosh, Joseph
Han, Guangchun
Wang, Ruiping
Santos, David
Badillo, Maria
Leeming, Angela
Chen, Zhihong
Hartig, Kimberly
Bigcal, John
Lee, Hun
Steiner, Raphael Eric
Romaguera, Jorge Enrique
Jain, Preetesh
Nomie, Krystle
Futreal, Andy
Wang, Linghua
Wang, Michael
BLOOD, 2020, 136

← 1 2 3 4 5 →